Yuehong Kong
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol).
Journal: Technology in cancer research & treatment
Published: March 13, 2026
Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol).
Journal: Translational lung cancer research
Published: February 14, 2026
Efficacy and safety of combined RANKL and PD-1 inhibitors in bone metastases: a retrospective study.
Efficacy and safety of combined RANKL and PD-1 inhibitors in bone metastases: a retrospective study.
Journal: Translational cancer research
Published: February 08, 2026
Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).
Journal: Technology in cancer research & treatment
Published: November 27, 2025
Safety and efficacy of PRaG therapy in elderly cancer patients.
Journal: Immunotherapy advances
Published: November 19, 2025
A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study.
Journal: Technology in cancer research & treatment
Published: November 18, 2025
Circulating T-lymphocyte subsets as biomarkers for immune checkpoint inhibitors in solid tumors.
Journal: Clinical and experimental immunology
Published: August 10, 2025
Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer.
Journal: Cancer management and research
Published: July 24, 2025
Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies.
Journal: Cancer immunology, immunotherapy : CII
Published: February 28, 2025
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).
Journal: Technology in cancer research & treatment
Published: July 25, 2024
The relationship between splenic dose and radiation-induced lymphopenia.
Journal: Journal of radiation research
Published: January 18, 2024
Last Updated: 09/26/2026